Track ABL Bio Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ABL Bio Inc. 298380.KQ · Stock Open ABL Bio Inc. in new tab

111900.00 KRW
Add to portfolio
ROE
-14.95
Beta
0.33
Target Price
223200.00 KRW
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Debt/Equity30.27
% Insiders24.520%
Growth
Revenue Growth5.07%
Estimates
Forward P/E522.29
Target Mean Price223200.00

DCF Valuation

Tweak assumptions to recompute fair value for ABL Bio Inc. (298380.KQ)
Currency: KRW
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

ABL Bio Inc. Logo ABL Bio Inc. Analysis (298380.KQ)

South Korea Healthcare Official Website Stock

Is ABL Bio Inc. a good investment? ABL Bio Inc. (298380.KQ) is currently trading at 111900.00 KRW. Market analysts have a consensus price target of 223200.00 KRW. This suggests a potential upside from current levels.

Investor FAQ

Does ABL Bio Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is ABL Bio Inc.?

ABL Bio Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.

Exchange Ticker
KOE 298380.KQ
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion